(The 4th CIIE) Exploring the Pavilion｜The CIIE Stage "Intensive and New" Medical Enterprises Cooperation "Out of Circle" and "Building Circle"
China News Agency, Shanghai, November 9th (Reporter Li Shuzheng and Li Jiajia) The 70,000 square meters medical equipment and medical care exhibition area is not the largest among the exhibition areas of the 4th CIIE, but it is "global new" and "Asian new" The number of "China New" products has hit a record high.
On the stage of the “Intensive and New” Expo, the stories of medical companies “out of the circle” and “building the circle” are happening.
"In the past few days, many purchase groups from all over the world have come back and forth to learn about our products. The stage of the CIIE has given us an opportunity to understand the needs of both parties and communicate." Mentioning the "out of the circle" of its own products, Ailang Medical Shi Hua, vice president of the world and general manager of the China region, beamed with joy.
As the world's leading manufacturer and marketer of interventional therapy products, Airang Medical presented 9 products at the CIIE, 3 of which have not yet been listed in China. This time it is the first innovative product in China.
The picture shows the booth of Airang Medical at this CIIE.
Photo courtesy of Airang Medical
Working in a relatively niche segmented field, it is not easy to "get out of the circle".
"In the past two years, we have covered most of China's provincial capital cities, but for the western regions, our coverage needs to be improved." Shi Hua said.
The big stage of the CIIE has further strengthened the "diffusion power" of niche premium products.
Shi Hua said that the significant spillover effect of the CIIE has allowed Airang Medical to significantly increase its brand awareness in the industry, attract more outstanding talents, and attract a number of local companies to communicate and cooperate.
On the other side of the Expo stage, many well-known companies are joining forces to build a pharmaceutical ecosystem.
Roche Diagnostics China and GE Healthcare China announced at the 4th China International Import Expo that they have formally reached cooperation in the non-public medical field.
Photo courtesy of Roche Diagnostics
At this CIIE, Roche Diagnostics China and GE Healthcare China formally reached their non-public medical field cooperation.
The cooperation aims to integrate the global in vitro diagnostic and imaging diagnostic solutions of both parties and jointly promote the application of innovative diagnostic technologies with high medical value in China's non-public medical and health institutions.
And Danaher's operating company Radiometer and AstraZeneca China also announced a strategic cooperation on the joint construction of the whole course of kidney disease management.
"Danaher actively contributes to the high-quality development of China's medical services, and supports the improvement of medical institutions' diagnosis and treatment capabilities and the construction of multi-faceted disciplinary capabilities." Bring more integrated diagnosis and treatment solutions to patients.
On the big stage of the China International Import Expo, cross-industry cooperation is also "good show".
At this CIIE, Sanofi, a multinational pharmaceutical company, not only launched a new atrial fibrillation drug Metadragon, but also signed a letter of intent for cooperation with the insurance company Magnesium Health to create a full-course management project for patients with atrial fibrillation.
Ping An Health and AstraZeneca also signed a strategic cooperation agreement at the CIIE, and the two parties announced that they would jointly create an integrated chronic disease management model.
Shandi has also reached a strategic alliance with Roche, a top global pharmaceutical company, and this has become a breakthrough for Shandi's official entry into the pharmaceutical industry.
At this CIIE, Shandi and Roche announced a strategic alliance.
“Innovation in the health field is inseparable from the three links of prevention, intervention, and payment. On the prevention side, we have chosen a health check; on the payment side, we focus on health insurance for the elderly. On the intervention side, I think “medicine” is the field Strategic products.” said Wu Hongxing, founder and CEO of Shandi.
"The medical system should not only focus on drugs and technology, but also on the'experience' of the entire ecosystem and patients." Liu Jing, general manager of Sanofi's China Innovation and Core Business Department, said in an interview with a reporter from China News Agency. Pharmaceutical companies provide innovative drugs and technologies, diagnostic companies ensure accurate diagnosis, and insurance companies provide financial support.
In addition, coupled with digital wearable devices, follow-up big data, patient care projects, etc., a medical "ecosphere" can be built around patient experience.
In the eyes of many companies, both "out of the circle" and "building of the circle" are rooted in cooperation.
"The annual CIIE is not only the focus of our results report, but also the starting point for our negotiation and cooperation." said Wang Lei, AstraZeneca's global executive vice president and president of international business and China.
(over)